RICHARD QUINTILIANI, M.D.; CHARLES H. NIGHTINGALE, Ph.D.
After 5 years of use, cefazolin can be considered similar to cephalothin as a therapeutic agent and in its potential for adverse reactions. When cefazolin and cephalothin are compared by appropriately designed clinical trials, neither cefazolin's slightly greater in-vitro susceptibility to staphylococcal beta-lactamase inactivation, nor its slightly greater microbiologic activity for some enterobacteraciae has been shown to result in any readily apparent therapeutic differences. The important differences between cefazolin and cephalothin—and this is also probably true with respect to cephapirin and cephradine—are not in therapeutic effectiveness, microbiologic activity, or toxicity but rather in pharmacokinetics and cost-effectiveness.
QUINTILIANI R, NIGHTINGALE CH. Drugs Five Years Later: Cefazolin. Ann Intern Med. ;89:650–656. doi: 10.7326/0003-4819-89-5-650
Download citation file:
Published: Ann Intern Med. 1978;89(5_Part_1):650-656.
Emergency Medicine, Infectious Disease.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use